Tadalafil

Tadalafil (CAS 171596-29-5), also referenced in development literature as IC351, is a PDE5 inhibitor active pharmaceutical ingredient used in the treatment of erectile dysfunction and pulmonary arterial hypertension.

It functions as the pharmacologically active component in finished oral dosage forms and is sourced by formulators and importers as a bulk API or pharmaceutical intermediate for various industrial applications.

In prescription drug manufacturing, the compound is formulated into film-coated tablets at defined dosage strengths for both on-demand and daily-use therapeutic regimens across global markets.

Compounding pharmacies source the bulk API to prepare customized dosage forms for patients with specific clinical requirements. This ensures flexibility in treatment options for diverse patient populations.

Pulmonary arterial hypertension treatments represent a distinct therapeutic segment, where the ingredient is incorporated into once-daily oral formulations targeting vascular smooth muscle relaxation and improved blood flow.

Research and analytical laboratories also procure it as a reference standard or intermediate for method development and quality control testing to ensure the safety and efficacy of final products.

The substance is supplied as a white to off-white crystalline powder. It is available in API-grade quality aligned with USP and EP monograph specifications, which are the primary benchmarks required.

Bulk quantities are typically offered in kilogram-scale packaging, with documentation including CoA, impurity profiles, and relevant DMF references to support regulatory compliance and manufacturing standards.